Market Overview

UPDATE: Piper Jaffray Initiates Coverage on Alexza Pharmaceuticals to Neutral Rating, $5 PT

Related ALXA
Benzinga's M&A Chatter for Tuesday May 10, 2016
Worst Performing Industries For April 26, 2016

In a report published Friday, Piper Jaffray & Co. initiated coverage on Alexza Pharmaceuticals (NASDAQ: ALXA) with a Neutral rating and $5.00 price target.

Piper Jaffray noted, “We are initiating coverage on Alexza with a Neutral rating and 12-month price target of $5. Alexza reformulates drugs for pulmonary delivery with its novel device, Staccato, that enables rapid absorption. For recently approved Adasuve (Staccato loxapine for agitation), we anticipate a U.S. partner in 1H13 and launch by 3Q13, and European approval in 1Q13. While we view Adasuve to be a value-added offering, uncertainty of limitations on settings for use, as well as timing, put us on the sidelines until we see more granularity on marketing initiatives to combat commercial hurdles or next steps with the pipeline. In the interim, we have established a placemarker sum of the parts valuation of $2.50/share for Adasuve and assigned $2.50/share for the Staccato platform.”

Alexza Pharmaceuticals closed on Thursday at $4.96.

Latest Ratings for ALXA

Aug 2014Roth CapitalDowngradesBuyNeutral
Jul 2013JMP SecuritiesAssumesMarket Outperform
Apr 2013PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for ALXA
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Initiation Analyst Ratings


Related Articles (ALXA)

View Comments and Join the Discussion!

Partner Center